Oxycodone

# Research Output: Oxycodone

---

## Chemical Identity

**PubChem CID:** 5284603 (confirmed via API) [Ref 1]
**Molecular Formula:** C₁₈H₂₁NO₄ (confirmed; matches brief) [Ref 1]
**Molecular Weight:** 315.4 g/mol (315.36 precise) [Ref 1]
**CAS Number:** 76-42-6 [Ref 37]
**IUPAC Name:** (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one (confirmed; matches brief) [Ref 1]
**InChIKey:** BRUQQQPBMZOVGD-XFKAJCMBSA-N [Ref 1]
**SMILES:** N1([C@H]2[C@]3([C@@]4([C@@H](Oc5c4c(ccc5OC)C2)C(=O)CC3)CC1)O)C [Ref 37]

**Physical Properties:**
- Melting point: 218–220°C (crystalline solid) [Ref 37]
- Appearance: Long rods from EtOH (ethanol crystallization) [Ref 37]
- pKa: 8.53 (at 25°C) [Ref 37]
- Density: ~1.2164 g/cm³ (estimate) [Ref 37]
- Storage: 2–8°C [Ref 37]
- Aqueous solubility: Limited; readily soluble in DMF (20 mg/mL), DMSO (10 mg/mL) [Ref 37]

**Stereochemistry:** Single, defined enantiomer with four stereocenters: 4R, 4aS, 7aR, 12bS. Oxycodone exists as a single stereoisomeric form — not a racemate. The systematic name and confirmed IUPAC designation unambiguously specify this configuration. [Ref 1]

**Chemical Class:** Morphinan; substituted morphinan. Semisynthetic derivative of thebaine (a naturally occurring opium alkaloid). [Ref 4]

**Discrepancies vs. seed data:** SMILES and PubChem CID were absent from the brief. Both are now confirmed from the PubChem API. Formula, weight, and IUPAC all match. No contradictions found.

---

## Pharmacology

### Receptor Binding & Mechanism of Action

Oxycodone is a semisynthetic opioid that primarily acts as an agonist at the mu-opioid receptor (MOR), which is a Gi/Go-protein coupled receptor (GPCR). Upon binding, oxycodone activates Gi-protein signaling, leading to inhibition of adenylyl cyclase (reducing cAMP), activation of G-protein-coupled inward rectifying potassium channels (GIRK) causing membrane hyperpolarization, and inhibition of voltage-gated calcium channels — collectively suppressing neuronal excitability and nociceptive transmission. Herman et al. [Ref — MOR review, PMID 31855381] provide a comprehensive mechanistic overview of MOR signaling.

**Primary targets:** MOR (mu-opioid receptor) — confirmed as highest-affinity target [Ref 7; Ref 38]

**Secondary targets:** Kappa-opioid receptor — specifically the kappa₂b subtype. Nielsen et al. (2007) demonstrated in rat brain membrane radioligand binding studies that oxycodone displaces [³H]bremazocine (kappa₂-selective) with relatively high affinity in MOR/DOR-depleted membranes, suggesting kappa₂b agonism. This activity was abolished by leu-enkephalin (kappa₂b ligand), and was not observed for mu-selective ligand CTOP or delta-selective DPDPE. These authors also showed that intrathecal oxycodone antinociception in neuropathic pain rats was abolished by the kappa-selective antagonist nor-BNI, not by mu-selective naloxonazine. [Ref 2]

**Debate on primary receptor:** The Nielsen et al. (2007) [Ref 2] data suggesting kappa₂b as the primary mechanistic target in neuropathic pain contrasts with Beardsley et al. (2004) [Ref 7], who showed in preclinical abuse liability studies that oxycodone generalizes to heroin discriminative stimulus and has morphine cross-dependence, arguing for primarily MOR-mediated effects. Olson et al. (2019) [Ref 3], in a comprehensive multi-receptor screening of 9 clinically used opioids including oxycodone, found oxycodone acts primarily via MOR with no novel receptor interactions (unlike buprenorphine or hydrocodone). Lemberg et al. (2010) [Ref 12], in a clinical pharmacodynamic study, found that CYP2D6 inhibition with paroxetine (which blocked oxymorphone formation) did not significantly change oxycodone analgesia, confirming that analgesia in humans is driven by the parent compound's direct MOR activity — not by metabolite formation. **Consensus:** Oxycodone functions primarily as a MOR agonist at therapeutic doses; the kappa₂b activity observed by Nielsen et al. may be more relevant in neuropathic conditions or contribute to differential effects vs. morphine.

**Active metabolite — Oxymorphone:** Formed via CYP2D6 O-demethylation, oxymorphone is a potent and selective MOR agonist with Kd ~1.7 nM in mouse brain membranes and Bmax ~147 fmol/mg tissue [Ref 6]. Binding is completely abolished in MOP receptor knockout mice and in triple knockout mice, with DOP and KOP knockout mice retaining binding — confirming oxymorphone as a selective MOR ligand [Ref 6]. Despite its high MOR potency, the CYP2D6 inhibitor paroxetine dramatically reduces oxymorphone AUC by 67% without meaningfully altering oxycodone analgesia [Ref 12], indicating oxymorphone makes a minor clinical contribution.

**Inactive/weak metabolite — Noroxycodone:** Formed via CYP3A4 N-demethylation; weak analgesic activity [Ref 4; Ref 10].

**Tolerance mechanism:** Melief et al. (2010) [Ref 5] established that oxycodone tolerance proceeds via G-protein receptor kinase 3 (GRK3)-mediated MOR desensitization — the same pathway as fentanyl and methadone — distinct from the JNK pathway used by morphine. This provides a mechanistic basis for incomplete cross-tolerance between oxycodone and morphine at the cellular level, despite shared MOR agonism.

**Reward/reinforcement:** Oxycodone activates the mesolimbic dopamine system via MOR. Dopamine D3 receptor (D3R) antagonism attenuates oxycodone self-administration and reinstatement of oxycodone-seeking behavior in rats [Ref 26]. DeltaFosB expression in the nucleus accumbens shell correlates with oxycodone physical dependence [Ref 25].

### Pharmacokinetics

**Oral bioavailability:** 60–87% [Ref 4]. This is substantially higher than morphine (~20–30%) due to reduced first-pass metabolism.

**Tmax:**
- Immediate-release oral: ~1–1.5 hours
- Controlled-release (CR/ER): ~2–3 hours [Ref 1; Ref 4]

**Plasma half-life:**
- Immediate-release: 3–5 hours [Ref 4; Ref 38]
- Controlled-release: approximately 12 hours [Ref 4]
- Note: Kinnunen et al. (2019) [Ref 1] note that basic PK data largely originate from 1990s studies; consult updated data for special populations.

**Protein binding:** ~45% (primarily to albumin and alpha-1-acid glycoprotein) [Ref 38]

**Volume of distribution (Vd):** 2.6 L/kg [Ref 38]

**Metabolism:**
- **Primary pathway (CYP3A4):** N-demethylation to noroxycodone — quantitatively the major route. Romand et al. (2017) [Ref 10] determined intrinsic clearance (Vd) of ~1.46 µL/min/mg for CYP3A4-mediated formation in human liver microsomes.
- **Secondary pathway (CYP2D6):** O-demethylation to oxymorphone — minor route; intrinsic clearance ~0.35 µL/min/mg [Ref 10].
- **Phase II (UGT2B7):** Glucuronidation to oxycodone-3-glucuronide — primarily by UGT2B7, secondarily by UGT2B4 [Ref 10].
- **CYP2C19:** Also contributes to metabolite ratios (6.9-fold CYP2D6 UM vs PM oxymorphone/oxycodone ratio; 1.6-fold CYP2C19 UM vs PM ratio) [Ref 9].

**Genetic variability:** CYP2D6 ultrarapid metabolizers (UMs) produce ~6.9× more oxymorphone than poor metabolizers (PMs) — the largest pharmacogenomic effect on oxymorphone formation [Ref 9]. CYP2D6 PMs are ~5-fold more likely to have oxymorphone-negative urine specimens [Ref 9]. Despite this, clinical analgesia is not significantly changed by CYP2D6 genotype in most patients [Ref 12; Ref 8].

**Drug-drug interactions (PK):**
- CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, erythromycin): Substantially increase oxycodone and metabolite exposure — most clinically significant [Ref 11; Ref 38]
- CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, enzalutamide): Markedly decrease oxycodone exposure; may cause treatment failure [Ref 11; Ref — enzalutamide, PMID 37162620]
- CYP2D6 inhibitors (paroxetine, fluoxetine): Reduce oxymorphone production; no clinically significant analgesic change [Ref 12]
- H₂ blockers and proton pump inhibitors: In vitro CYP inhibition; potential for modest in vivo interaction at therapeutic concentrations [Ref — Moody 2013, PMID 23857299]
- Azole antifungals: CYP3A4 inhibition potential; ketoconazole and voriconazole have greatest clinical potential [Ref — Moody 2015, PMID 25868557]

**Intranasal route:** Takala et al. (1997) [Ref 13] compared IV and intranasal oxycodone PK in healthy volunteers; intranasal administration provided measurable plasma concentrations with different Tmax compared to IV, consistent with transmucosal absorption. Specific intranasal bioavailability % was not reported in the available abstract. The clinical pharmacokinetics review (Kinnunen 2019) [Ref 1] covers transmucosal and epidural routes.

**Smoked route:** No published pharmacokinetic studies found for smoked oxycodone specifically. Duration data in the seed database (1–3 hours total for smoked) is plausible given rapid pulmonary absorption but lacks primary literature support. **FLAG: Seed data for smoked duration cannot be verified against primary sources.**

**Intravenous:** Complete bioavailability (100%), fastest onset (seconds to minutes). NCT02660229 (Phase IV trial) studied IV oxycodone vs. IV morphine for cancer pain.

**Excretion:** Primarily renal; oxycodone and metabolites are excreted in urine. Renal impairment may prolong elimination.

---

## History

**Discovery and synthesis (1916):** Oxycodone was first synthesized in 1916 by Martin Freund and Edmund Speyer of the University of Frankfurt (Goethe University), Germany, from thebaine — a naturally occurring but non-analgesic alkaloid of the opium poppy (Papaver somniferum). The motivation was to produce a compound with morphine-like analgesia but with reduced dependence potential — a goal that proved only partially achieved. [Ref 35]

**First clinical use (1917):** Oxycodone entered clinical use in Germany the year following its synthesis, in 1917 — approximately simultaneously with its development. Kinnunen et al. (2019) [Ref 1] confirm: "As oxycodone was synthesized in 1916 and taken to clinical use a year later, it has not undergone the same approval process required by today's standards."

**Introduction into US practice:** Oxycodone was introduced to US medicine in the 1950s, initially in combination products (e.g., Percodan: oxycodone + aspirin, introduced 1950; Percocet: oxycodone + acetaminophen, introduced 1976).

**OxyContin (extended-release, 1996):** Purdue Pharma received FDA approval for OxyContin — a 12-hour controlled-release formulation — in December 1995 (marketed 1996). This formulation delivered sustained opioid levels and was aggressively marketed for chronic non-cancer pain, contributing to a dramatic escalation in oxycodone prescribing. Kolodny et al. (2015) [Ref 18] document the resulting opioid crisis. By 2008, global oxycodone consumption had surpassed morphine [Ref 1].

**OxyContin reformulation (2010):** In August 2010, OxyContin was reformulated with a polyethylene oxide matrix (abuse-deterrent properties) that resists crushing, dissolving, and insufflation. Rodriguez et al. (2023) [Ref 27] and Wolff et al. (2020) [Ref 28] document that this reformulation reduced non-oral abuse; the latter study found no significant increase in heroin initiation as a consequence of reformulation.

**OxyContin withdrawal from Canada (2012):** Canada banned OxyContin in February 2012, replacing it with OxyNEO (crush-resistant formulation). Oxymorphone ER (Opana ER) emerged as a partial substitute [Ref — Delcher 2024, PMID 39623517].

**Regulatory/opioid epidemic context:** Oxycodone became emblematic of the US opioid epidemic. US opioid overdose deaths increased from ~4,000 in 1999 to >47,000 in 2017, with prescription opioids (including oxycodone) implicated in the first wave [Ref 20]. Prescribing reached its highest point around 2011 and subsequently declined [Ref 41].

---

## Subjective Effects

Published literature primarily addresses clinical analgesic effects and adverse events; controlled studies of subjective recreational/psychoactive effects are limited to small human studies.

**Analgesia (primary therapeutic effect):** Oxycodone provides dose-dependent suppression of nociceptive and neuropathic pain via MOR activation in the dorsal horn (presynaptic inhibition of excitatory neurotransmitter release) and supraspinal pathways [Ref — MOR review, PMID 31855381; Ref 4].

**Euphoria and reward:** Oxycodone activates mesolimbic dopamine pathways via MOR, producing euphoria that is central to its abuse liability [Ref 7; Ref 26]. Mogali et al. (2021) [Ref 34] demonstrated positive subjective drug effects in non-dependent recreational opioid users; minocycline (a glial activation inhibitor) attenuated these responses, implicating glia in oxycodone reward.

**Sedation:** Prominent CNS depressant effect; Hirai et al. (2025) [Ref 33] found oxycodone was disproportionately associated with drowsiness/sedation compared to fentanyl, hydromorphone, tapentadol, and morphine in palliative care databases.

**Adverse subjective effects compared to morphine:** Ordóñez Gallego et al. (2007) [Ref 4] note that oxycodone causes somewhat **less nausea, hallucinations, and pruritus than morphine**, though constipation and sedation are prominent.

**Constipation:** Near-universal in opioid users; mediated by peripheral MOR activation in the gut, reducing motility. Particularly dose-dependent and does not resolve with tolerance, unlike most CNS effects [Ref 31].

**Nausea:** Common, especially on initiation. Tends to decrease with continued use [Ref 4].

**Respiratory depression:** Dose-dependent, MOR-mediated; the primary cause of opioid overdose death. Wiebelhaus et al. (2016) [Ref 45] and Raleigh et al. (2017) [Ref 49] both confirm this mechanism is naloxone-reversible.

**Duration data from published studies:**
- Oral immediate-release: onset ~30–60 min, peak ~1–1.5h, duration ~4–6h [consistent with Ref 4]
- Oral controlled-release: peak ~2–3h, duration ~12h
- IV: Near-immediate onset, duration 3–5h
- Intranasal: More rapid onset than oral [Ref 13]; specific onset data not confirmed in extracted abstracts

**⚠️ FLAG on Primary ROA:** The seed data designates "primary ROA: insufflated" — this is inconsistent with published medical and pharmacological literature, where oral is the primary prescribed and most commonly studied route. Insufflated use is predominantly associated with non-medical misuse/abuse, particularly of crushed immediate-release or (historically) extended-release tablets. The generation agent should clarify in the article that oral is the clinical primary route, while intranasal is the primary non-medical route of misuse.

---

## Safety & Toxicity

### Acute Toxicity

**Primary toxidrome:** Respiratory depression, decreased level of consciousness, miosis (pinpoint pupils), bradycardia, hypotension, hypothermia, muscle flaccidity, cold/clammy skin. Death occurs from respiratory failure [Ref 38].

**LD50:** No published human lethal dose data available. Animal LD50 data for oxycodone specifically were not retrieved from the searches conducted. **FLAG: LD50 value not confirmed from primary sources.** Toxicity is classified as high in the seed data, consistent with the clinical literature on overdose deaths, but a specific LD50 value cannot be cited.

**Therapeutic index:** Narrow. Oxycodone has a narrow therapeutic index, particularly in opioid-naïve individuals. Respiratory depression can occur within the therapeutic dose range in sensitive individuals [Ref 48].

**Overdose epidemiology:** Cone et al. (2003) [Ref 14] analyzed 1,014 oxycodone-involved postmortem cases: 90.6% were drug abuse-related; **96.7% involved multiple drugs** (polydrug deaths). The most prevalent combinations were oxycodone + benzodiazepines, alcohol, cocaine, other narcotics, marijuana, or antidepressants. Only 30 single-drug deaths (3.3% of abuse deaths) involved oxycodone as the sole substance, suggesting that pure oxycodone fatality at recreational doses is uncommon compared to polydrug toxicity.

**Overdose management:**
- **First-line reversal: Naloxone** (IV, IM, intranasal, or subcutaneous). Naloxone completely reverses oxycodone-induced respiratory depression [Ref 49].
- Repeat naloxone dosing may be necessary because naloxone's duration of action (30–120 min) is shorter than oxycodone's (3–5h half-life) [Ref 38].
- As of 2014, approximately 26,463 opioid overdose reversals have been documented with community naloxone programs in the US [Ref 23].
- Recovery position for unconscious individuals prior to naloxone availability.

**Opioid-induced constipation (chronic):** Permanent peripheral MOR activation in the gastrointestinal tract; does not resolve with tolerance. Management includes laxatives, oxycodone-naloxone combinations, or peripherally acting MOR antagonists (PAMORAs) [Ref 31; Ref 32].

**Immunosuppression:** High-dose chronic opioid use is associated with immunosuppressive effects; clinical relevance in elderly is discussed [Ref 48].

**Endocrine effects:** Chronic opioid use can suppress the hypothalamic-pituitary-gonadal axis, resulting in reduced testosterone (men) and estrogen (women), contributing to sexual dysfunction, fatigue, and osteoporosis. Consistent with "sexual arousal suppression" in effects taxonomy.

**Neonatal opioid withdrawal syndrome (NOWS):** Oxycodone use during pregnancy is associated with NOWS in newborns; neonates exposed to oxycodone in utero typically show symptom onset by day of life 0–1 and may require pharmacological treatment [Ref 46]. Perinatal oxycodone exposure also causes long-term sex-dependent neurodevelopmental effects in animal models [Ref — Minakova 2022, PMID 36269379].

**Pharmacogenomics-related toxicity:** CYP2D6 ultrarapid metabolizers produce more oxymorphone and may experience enhanced side effects at standard doses [Ref 9]. This is important for prescribing safety.

---

## Harm Reduction

**Do not combine with CNS depressants:** The greatest risk of oxycodone-related death is from combination with other CNS depressants (benzodiazepines, alcohol, GHB/GBL, other opioids). Most oxycodone deaths involve polydrug combinations [Ref 14].

**Naloxone access:** All oxycodone users and their close contacts should have naloxone available. Community naloxone programs have reversed over 26,000 overdoses in the US [Ref 23]. Intranasal, IM, and auto-injector formulations are available. Know to call emergency services and administer naloxone if someone is unresponsive, breathing slowly, or has pinpoint pupils.

**Start low and go slow:** Opioid-naïve individuals should begin at the lowest effective dose. Tolerance to respiratory depression develops more slowly than tolerance to euphoria, creating risk when doses are escalated recreationally.

**Do not use alone:** Opioid overdose is frequently fatal when no one is present to administer naloxone or call emergency services.

**Extended-release formulations — never crush, chew, or dissolve:** Crushing extended-release formulations eliminates the controlled-release mechanism and can deliver a dose-dumped bolus. The pre-2010 OxyContin was particularly dangerous when crushed; the reformulated version (polyethylene oxide matrix) resists crushing for inhalation/injection but oral crushing still substantially increases Cmax [Ref 27; Ref 28].

**Drug checking:** In the illicit drug supply, opioids (including counterfeit oxycodone pills) are frequently adulterated with fentanyl or other synthetic opioids. Fentanyl test strips detect contamination and are recommended as a harm reduction tool.

**Contraindications (absolute):**
- Respiratory depression (pre-existing)
- Acute bronchospasm or hypercarbia
- Known hypersensitivity to oxycodone
- Known or suspected paralytic ileus or gastrointestinal obstruction [Ref 38]

**Relative contraindications/cautions:**
- Concurrent MAOI use (risk of serotonin syndrome and enhanced CNS depression)
- Concurrent use of CYP3A4 inhibitors (substantially increases oxycodone exposure)
- Hepatic or renal impairment (reduced clearance; requires dose adjustment)
- Pregnancy (NOWS risk) [Ref 46]
- Elderly (reduced clearance, increased sensitivity)
- History of substance use disorder

**Respiratory monitoring:** In any clinical setting, respiratory rate and oxygen saturation should be monitored when oxycodone doses are initiated or escalated.

---

## Tolerance & Dependence

### Tolerance

**Development:** Tolerance develops with repeated use, requiring increasing doses to achieve the same analgesic or euphoric effect [Ref 4; Ref 41]. Tolerance to sedation, nausea, and respiratory depression typically develops faster than tolerance to constipation.

**Cellular mechanism:** Oxycodone tolerance is mediated by GRK3 (G-protein receptor kinase 3)-dependent MOR desensitization and internalization — the same pathway as fentanyl and methadone, and distinct from the JNK pathway that mediates morphine tolerance. Melief et al. (2010) [Ref 5] demonstrated that GRK3 knockout mice show abolished oxycodone tolerance but not morphine tolerance.

**Cross-tolerance:** Full cross-tolerance with all MOR agonists (morphine, hydromorphone, fentanyl, heroin, etc.). The seed data states cross-tolerance with opioids — this is confirmed.

**Clinical tolerance data:** The seed data states tolerance half-life of 5 days and full reset at 1.5 weeks. These figures are plausible given the 3–5h plasma half-life but are not directly confirmed from a primary human study in searches conducted. **FLAG: Tolerance half-life (5 days) and full reset (1.5 weeks) seed values not verified against a primary published source.**

### Dependence

**Physical dependence:** Develops with prolonged use. Animal models validate physical dependence: escalating doses over 8+ days produce robust, dose-dependent naloxone-precipitated withdrawal syndrome including jumping, paw tremors, diarrhea, and weight loss [Ref 24; Ref 44].

**Withdrawal syndrome characteristics:** Opioid withdrawal from oxycodone follows typical opioid withdrawal timelines. Clinical features include anxiety, yawning, lacrimation, rhinorrhea, diaphoresis, myalgia, nausea, vomiting, diarrhea, abdominal cramping, piloerection, restlessness, insomnia, and dysphoria. Withdrawal is rarely life-threatening but intensely uncomfortable.

**Psychological dependence:** The rewarding effects (euphoria via mesolimbic dopamine) drive psychological dependence, compulsive use, and craving. DeltaFosB expression in the nucleus accumbens shell — a molecular marker of addiction — is induced by oral oxycodone consumption [Ref 25].

**Dependence liability:** Beardsley et al. (2004) [Ref 7] showed oxycodone produces cross-dependence with morphine (fully suppresses morphine withdrawal in rhesus monkeys), confirms it as a positive reinforcer (self-administration in rats), and generalizes to heroin discriminative stimulus. These studies pre-date awareness of the opioid epidemic and establish that oxycodone has abuse liability comparable to classic opioids.

**Addiction rates in clinical populations:** Vowles et al. (2015) [Ref 43] meta-analysis found misuse rates of 21–29% and addiction rates of 8–12% in chronic pain patients receiving opioids (including oxycodone). These rates are relevant for risk communication.

**Treatment of opioid use disorder (OUD):** Buprenorphine/naloxone and methadone are first-line maintenance treatments for oxycodone-related OUD [Ref 50; Ref — Mattick 2014, Cochrane review]. Naltrexone (antagonist therapy) is an alternative. Extended-release oxycodone with sequestered naltrexone (ALO-02) was studied in Phase III trials (NCT01571362) as an abuse-deterrent formulation.

---

## Interactions

### Established High-Risk Interactions

**Alcohol (ethanol) — Lethal risk:**
Combined central nervous system depression and respiratory depression. The 2003 postmortem database (Cone et al.) [Ref 14] found alcohol to be among the most common co-intoxicants in oxycodone-related deaths. Extended-release oxycodone formulations do not show significant dose-dumping with alcohol at tested concentrations (Burger et al. 2020) [Ref 29], meaning the interaction is primarily pharmacodynamic (additive CNS depression) rather than PK-mediated. ⚠️ Seed data rates as "lethal" — confirmed.

**Benzodiazepines (alprazolam) — Dangerous:**
Zacny et al. (2012) [Ref 15] conducted a human controlled study (healthy volunteers) showing augmented abuse-related effects and psychomotor impairment with oxycodone + alprazolam. Ji et al. (2021) [Ref 47] found synergistic pharmacodynamic interaction via oxycodone's MOR binding and diazepam's KOR binding, with combined receptor occupancy exceeding either drug alone. Benzodiazepines were the most common co-intoxicant in oxycodone deaths [Ref 14]. ⚠️ Seed data rates as "dangerous" — confirmed; consider whether this warrants upgrading to "lethal."

**GHB/GBL — Lethal risk:**
GHB (gamma-hydroxybutyric acid) and GBL (gamma-butyrolactone, a GHB prodrug) are potent CNS depressants acting via GABA-B receptors and GHB receptors. Combination with opioids produces profound synergistic CNS and respiratory depression. No oxycodone-specific GHB interaction studies were found in the literature search. The interaction is mechanistically well-supported (dual CNS depressant). ⚠️ **FLAG: No published oxycodone+GHB/GBL interaction study found. Lethal rating is mechanistically plausible but not verified from a primary oxycodone-specific source.** The seed data rates as "lethal" — this is likely accurate but should be flagged.

**Tramadol — Lethal risk:**
Tramadol is both a weak opioid agonist and a serotonin-norepinephrine reuptake inhibitor (SNRI). Combining with oxycodone adds: (1) additive opioid respiratory depression, and (2) serotonin syndrome risk if concomitant serotonergic exposure. Baldo (2018) [Ref 30] reviews opioids and serotonin toxicity, finding oxycodone clinical cases of serotonin syndrome despite not being SERT inhibitory in vitro. No oxycodone+tramadol specific study was found. ⚠️ **FLAG: No published oxycodone+tramadol-specific study found. Lethal rating is mechanistically plausible (dual opioid + serotonin risk) but not verified from a primary source.** Seed data rates as "lethal."

**Ketamine — Unknown/Possible risk:**
Ketamine is an NMDA receptor antagonist and mild dissociative anesthetic. At subanesthetic doses (recreational), ketamine can contribute to CNS depression. At high anesthetic doses, it causes respiratory depression. The combination with opioids is used clinically (opioid-sparing); however, at recreational doses the interaction risk depends on dose context. ⚠️ **FLAG: Seed data rates as "lethal" — this may be overstated. Clinical use of sub-anesthetic ketamine with opioids is common and does not routinely cause fatal respiratory depression. The lethal rating likely refers to high-dose recreational co-use. Insufficient published evidence found to verify or refute this specific rating. Recommend editorial review.**

### Moderate-Risk Interactions

**Cannabis — Caution:**
Cannabis (cannabinoids) and opioids have overlapping analgesic pathways. Preclinical studies show cannabidiol can potentiate oxycodone analgesia via oral co-administration [Ref — Brice-Tutt 2025, PMID 39914591]. Clinical studies show opioid-sparing effects of THC in some contexts. Cannabis-use patients sometimes show higher postoperative opioid requirements (complex interaction). Combined CNS depression (sedation, psychomotor impairment) is the primary risk. ⚠️ Seed data rates as "caution" — this is appropriate given the complex and bidirectional evidence.

**Pregabalin — Caution (seed data: "unknown"):**
Gomes et al. (2017) [Ref 39] conducted a population-based nested case-control study finding that gabapentin co-prescription with opioids significantly increases risk of opioid-related death. Lyndon et al. (2017) [Ref 40] found increased respiratory depression risk with gabapentinoid + opioid combination in heroin users. **Recommendation: Upgrade interaction from "unknown" to "caution."** The specific oxycodone+pregabalin combination is not characterized in a primary study, but the class effect is well-established.

**Nitrous oxide — Unknown:**
No published data found specific to oxycodone + nitrous oxide interaction. Mechanistically, nitrous oxide is an NMDA antagonist with mild analgesic and euphoric properties; CNS depression combination with opioids is possible but not characterized in the available literature. Seed data "unknown" rating is appropriate.

**PCP — Unknown:**
No published data found specific to oxycodone + phencyclidine interaction. PCP is an NMDA antagonist; potential combined dissociation and opioid CNS depression. Seed data "unknown" rating is appropriate.

### CYP-Mediated Drug Interactions

Clinically significant CYP-mediated interactions are detailed in the Pharmacokinetics section above. Key points:
- CYP3A4 inhibitors can dramatically increase oxycodone exposure → increased risk of CNS depression and respiratory depression
- CYP3A4 inducers can dramatically decrease oxycodone exposure → risk of inadequate analgesia (and withdrawal)

### Serotonin Syndrome Risk

Baldo (2018) [Ref 30] confirmed that clinical serotonin syndrome cases have been reported with oxycodone + serotonergic drugs (SSRIs, SNRIs, MAOIs), despite oxycodone not inhibiting SERT in vitro. Case reports include a case of serotonin syndrome with venlafaxine + oxycodone in an elderly patient [Ref — Erdem 2024, PMID 38694682]. Risk is lower than with tramadol (a known SERT inhibitor) but not zero. The FDA issued a 2016 Drug Safety Communication on opioids and serotonin toxicity.

---

## Legal Status

| Jurisdiction | Classification | Notes |
|---|---|---|
| **United States** | Schedule II (DEA Controlled Substances Act, 1970) | High abuse potential, accepted medical use; no refills permitted; requires written/electronic prescription. Oxycodone in combination products with low-dose opioid may carry different scheduling. [Ref 41] |
| **United Kingdom** | Class A drug; Schedule 2 Controlled Drug (CD2) | Misuse of Drugs Act 1971. Possession without prescription: up to 7 years. Supply/production: up to life imprisonment. Prescription-only with controlled drug requirements (quantity written in words and figures). [Ref 36] |
| **Australia** | Schedule 8 (Controlled Drug) | Therapeutic Goods Administration (TGA) / Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). Requires prescription; strict state regulations on prescribing. Possession without authority illegal. [Ref 36] |
| **Canada** | Schedule I (Controlled Drugs and Substances Act, CDSA) | OxyContin (original) withdrawn 2012; replaced by abuse-deterrent OxyNEO. Prescription required. [Ref 36] |
| **EU** | Varies by member state | Generally listed as prescription-only narcotic; controlled under national equivalents of UN Single Convention on Narcotic Drugs. |

**UN Convention:** Oxycodone is controlled under the 1961 Single Convention on Narcotic Drugs (Schedule I).

---

## Clinical Trials

Key completed and notable clinical trials identified:

| NCT ID | Title | Phase | Status | Sponsor | Relevance |
|---|---|---|---|---|---|
| NCT01571362 | ALO-02 (Oxycodone HCl + Naltrexone HCl) for Chronic Low Back Pain | Phase III | Completed | Pfizer | Abuse-deterrent extended-release; chronic pain |
| NCT00902837 | OXN PR vs. OxyPR for osteoarthritis pain and constipation | Phase III | Completed | Mundipharma | Oxycodone/naloxone for OIC; pain/bowel function |
| NCT00528177 | Morphine vs. Oxycodone for Postoperative Pain | Phase IV | Completed | Ullevaal University Hospital | Comparative efficacy/tolerability |
| NCT02660229 | OxyNorm IV vs. Morphine IV for Cancer Pain | Phase IV | Completed | Mundipharma Korea | Intravenous oxycodone for cancer pain |

**Active pipeline:** As of April 2026, oxycodone vaccine research continues (NCT04458545 is referenced for the oxycodone hapten vaccine at IND stage) [Ref 49].

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. No feedback items to assess.

---

## Gaps & Flags

### Data Points Not Verified from Primary Sources

1. **⚠️ LD50 data absent:** No specific LD50 values for oxycodone in any species were retrieved from the literature searches. The acute toxicity rating of "high" in the seed data is consistent with clinical evidence (fatal respiratory depression), but a specific LD50 number cannot be cited.

2. **⚠️ Ki/EC50 binding affinity values not confirmed numerically:** IUPHAR Guide to Pharmacology (ligandId 7093) was inaccessible. Olson et al. (2019) [Ref 3] and Nielsen et al. (2007) [Ref 2] establish MOR primary and kappa₂b secondary activity qualitatively and comparatively, but specific Ki values (in nM) at human opioid receptors were not extracted. The generation agent should note this gap and avoid fabricating specific Ki values.

3. **⚠️ Intranasal bioavailability % not confirmed:** Takala et al. (1997) [Ref 13] studied IV vs. intranasal PK but the abstract does not provide a specific bioavailability percentage for the intranasal route. General literature suggests ~45–75% (class estimate for intranasal opioids) but oxycodone-specific data not confirmed.

4. **⚠️ Tolerance half-life (5 days) and full reset (1.5 weeks):** Seed data values not found in primary published literature. These are plausible based on analogy with morphine tolerance models but are not verified from a primary oxycodone-specific human study.

5. **⚠️ Smoked oxycodone PK:** No published pharmacokinetic studies for smoked oxycodone were found. Seed data duration values for smoked route (1–3h total) are plausible but unverified.

### Contradictions / Discrepancies

6. **⚠️ Primary ROA listed as "insufflated" in seed data:** Published medical literature, clinical pharmacology reviews, and FDA approvals all designate oral as the primary route of administration. Insufflated (intranasal) use is the primary route of non-medical/recreational misuse, not the clinical primary route. Recommend correcting to: "primary ROA (clinical): oral; primary ROA (non-medical): insufflated."

7. **⚠️ Pharmacological class — kappa vs. mu:** The brief lists "kappa-opioid receptor agonist, mu-opioid receptor agonist." This is debated. Most evidence and clinical consensus supports MOR as the primary target; kappa₂b activity is a secondary/neuropathic-specific finding (Nielsen et al. 2007, rat preclinical). The generation agent should present this nuance — MOR primary, kappa contribution secondary and context-dependent.

### Interaction Ratings Requiring Review

8. **⚠️ Ketamine interaction "lethal":** Insufficient published evidence to support a "lethal" rating specifically for oxycodone + ketamine at recreational doses. This interaction is used clinically at sub-anesthetic ketamine doses without routine fatality. Recommend editorial review — may warrant downgrade to "caution" or "dangerous" unless evidence supports lethal classification.

9. **⚠️ Tramadol interaction "lethal":** Mechanistically plausible (combined respiratory depression + serotonin syndrome risk) but no oxycodone-specific study found. Serotonin syndrome is potentially life-threatening, supporting a high-risk rating, but "lethal" as a default interaction severity without a primary source should be flagged.

10. **⚠️ GHB/GBL interactions "lethal":** Mechanistically plausible (dual CNS depressant synergy) but no oxycodone-specific studies retrieved. The rating is consistent with class-level evidence for opioid + CNS depressant combinations.

11. **⚠️ Pregabalin interaction "unknown":** Evidence from Gomes et al. (2017) [Ref 39] and Lyndon et al. (2017) [Ref 40] supports upgrading this to **"caution."** Gabapentinoid co-prescription significantly increases opioid-related death risk in population studies.

12. **⚠️ Nitrous oxide and PCP interactions:** Insufficient published data for oxycodone-specific interaction. "Unknown" rating appropriate to retain.

### Sections Relying on Class Inference

13. **GHB/GBL interaction severity:** Based on class-level CNS depressant + opioid risk data, not oxycodone-specific evidence.

14. **Tramadol interaction severity:** Based on class-level opioid combination + tramadol serotonergic risk data.

15. **Physical properties (logP, aqueous solubility in mg/mL):** logP value not retrieved from primary sources; pKa confirmed at 8.53 from ChemicalBook [Ref 37] — this is a calculated estimate, not necessarily from a primary experimental measurement.